Johnson & Johnson currently boasts one of the largest lineups of multiple myeloma products. Since its first FDA approval of a drug for this type of blood cancer a decade ago, the pharmaceutical giant has expanded in this space with additional drugs representing different modalities. To Joshua Bauml, vice president, lung cancer area stronghold leader at J&J, the company’s experience in multiple myeloma is a blueprint for its strategy in lung cancer.

“Look at what we’ve done in multiple myeloma,” Bauml said. “We started an area where there was nothing and we’ve really built out a pipeline. And that’s exactly what we intend to do in lung cancer.”

J&J’s multiple myeloma portfolio is anchored by Darzalex. Today, that drug is not only J&J’s top-selling cancer product, it’s the company’s top dr

See Full Page